We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genomic Atlas of Human Plasma Proteome Publicized

By LabMedica International staff writers
Posted on 26 Jun 2018
Although plasma proteins have important roles in biological processes and are the direct targets of many drugs, the genetic factors that control inter-individual variation in plasma protein levels are not well understood.

Bringing in expression quantitative trait locus (QTL) and protein QTL data, biological pathway clues, drug database insights, and variants identified in prior genome-wide association studies, a team of scientists subsequently searched for plasma proteins contributing to common conditions, such as inflammatory bowel disease, as well as for potential drugs for altering these pathways.

A large team of scientists collaborating with those at the University of Cambridge (Cambridge, UK) characterized the genetic architecture of the human plasma proteome in healthy blood donors. More...
The study involved about 50,000 participants, and the team systematically quantified levels for thousands of proteins in plasma samples from 3,301 seemingly healthy, genotyped individuals. With these data, they uncovered more than 1,900 interactions between almost 800 genomic regions and nearly 1,500 proteins.

The scientists used the SOMAscan, an aptamer-based multiplex protein assay. They quantified plasma levels of 3,622 proteins in blood samples from 3,301 healthy donors. They set those proteome data alongside genetic profiles for the participants, searching for associations between plasma proteins and 10.6 million autosomal SNPs that were imputed or directly assessed using Affymetrix Axiom UK Biobank arrays. The team's analysis uncovered 1,927 associations involving 1,478 proteins and 764 regions in the genome. Most of those associations, 89%, had not been described previously.

The team noted that 502 of the protein-associated loci appeared to act locally, or in cis, while 228 had trans effects on plasma proteins. The remaining 34 loci appeared to have both cis and trans protein interactions. They validated 106 of 163 proposed protein QTLs using an Olink protein assay (Uppsala, Sweden; www.olink.com) on samples from another 4,998 individuals, noting that the cis pQTLs appeared more apt to replicate than those involving longer-range trans interactions. After exploring the overlap between the proposed pQTLs and expression QTLs reported in the past, the investigators incorporated information from prior genome-wide association study.

The authors concluded that by linking genetic factors to diseases via specific proteins, their analyses highlight potential therapeutic targets, opportunities for matching existing drugs with new disease indications, and potential safety concerns for drugs under development. The study was published on June 6, 2018, in the journal Nature.

Related Links:
University of Cambridge


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Candida Glabrata Test
ELIchrom Glabrata
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.